Loading
Parathyroid Disorders and Treatments / Cancer, Hypoxia, and Metabolism / Nanoplatforms for Cancer Theranostics · Journal article
Cancers · August 12, 2026
Raises a question worth testing. It does not answer one.
This is a conceptual overview of calcium-mediated vascular disruption as a theoretical oncology strategy, grounded in preclinical mechanistic evidence and emerging nanotechnology platforms. The authors identify promising preclinical feasibility but explicitly acknowledge that clinical translation faces unresolved challenges in biosafety, delivery precision, pharmacokinetics, and regulation, and report no clinical efficacy data.
Journal article.
Intracellular calcium elevation in endothelial cells promotes dysfunction, coagulation, mitochondrial collapse, oxidative stress, and apoptosis Calcium phosphate, calcium carbonate, and calcium peroxide nanoparticles exploit enhanced permeability and retention effect for selective tumor accumulation Hybrid platforms coupling calcium dysregulation with chemotherapy, photodynamic therapy, sonodynamic therapy, immunotherapy, or thermal ablation exhibit pronounced antitumor effects in preclinical models
No human or animal toxicity, pharmacokinetic, or biodistribution data provided Claims of reduced resistance and systemic toxicity are stated as theoretical advantages without supporting evidence
Clinicians should recognize this as an exploratory, mechanistically motivated approach currently limited to preclinical and theoretical stages; no direct clinical translation or patient-applicable evidence is presented. The framework may inform future drug development but does not support current therapeutic decisions.
This is a narrative review synthesizing preclinical mechanistic evidence and theoretical frameworks for calcium-mediated vascular disruption in cancer, without reporting new experimental or clinical data, efficacy endpoints, or comparative trials.
Clinicians should recognize this as an exploratory, mechanistically motivated approach currently limited to preclinical and theoretical stages; no direct clinical translation or patient-applicable evidence is presented. The framework may inform future drug development but does not support current therapeutic decisions.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Cancer therapy is increasingly focused on manipulating the tumor microenvironment rather than directly eradicating malignant cells. Vascular-targeting strategies are emerging, and calcium-mediated vascular disruption is an exciting approach through which rapid and irreversible blood flow shutdown can be achieved. Here, we overview the molecular and physiological basis of calcium signaling in vascular homeostasis and outline how unregulated calcium dysfunctions in endothelial cells compromise their functionality and represent therapeutic opportunities. Elevation of intracellular calcium concentrations in endothelial cells promotes their dysfunction, coagulation, mitochondrial collapse, oxidative stress, and ultimately apoptosis, resulting in catastrophic vascular depletion and secondary necrosis that follows such collapse. A promising area of calcium-mediated attack is the emergence of exciting nanotechnologies that result in the development of calcium phosphate, calcium carbonate, and calcium peroxide nanoparticles, exploiting the enhanced permeability and retention effect of nanoparticle therapeutics to achieve selective tumor accumulation and controlled calcium release. Indeed, hybrid therapeutic platforms that couple calcium dysregulation with chemotherapy, photodynamic therapy, sonodynamic therapy, immunotherapy, or thermal ablation can exhibit pronounced antitumor effects through synergistic means. There is good preclinical evidence for the feasibility of vascular collapse mediated via calcium dysregulation. The transition of calcium to the clinic faces hurdles in relation to biosafety, how to achieve precise delivery, pharmacokinetics, and regulatory harmonization. Compared to traditional vascular disrupting agents and anti-angiogenic therapies, calcium modalities can provide rapid occlusion of vessels, are less prone to resistance development, and potentially have less systemic toxicity. Overall, calcium-mediated vascular collapse is thus an exciting next-generation technology for the vascular-targeted treatment of cancer, and likely to play an important role in precision oncology therapeutics.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.